CN117255793A - 稠合四环类化合物、其制备方法及其在医药上的应用 - Google Patents

稠合四环类化合物、其制备方法及其在医药上的应用 Download PDF

Info

Publication number
CN117255793A
CN117255793A CN202280030759.7A CN202280030759A CN117255793A CN 117255793 A CN117255793 A CN 117255793A CN 202280030759 A CN202280030759 A CN 202280030759A CN 117255793 A CN117255793 A CN 117255793A
Authority
CN
China
Prior art keywords
cancer
compound
pharmaceutically acceptable
membered
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202280030759.7A
Other languages
English (en)
Chinese (zh)
Inventor
李心
沈峰
董怀德
陈阳
贺峰
陶维康
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Jiangsu Hengrui Medicine Co Ltd
Shanghai Hengrui Pharmaceutical Co Ltd
Original Assignee
Jiangsu Hengrui Medicine Co Ltd
Shanghai Hengrui Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jiangsu Hengrui Medicine Co Ltd, Shanghai Hengrui Pharmaceutical Co Ltd filed Critical Jiangsu Hengrui Medicine Co Ltd
Publication of CN117255793A publication Critical patent/CN117255793A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
CN202280030759.7A 2021-06-21 2022-06-21 稠合四环类化合物、其制备方法及其在医药上的应用 Pending CN117255793A (zh)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
CN202110687643 2021-06-21
CN2021106876438 2021-06-21
CN2021108801050 2021-08-02
CN202110880105 2021-08-02
CN2021110737758 2021-09-14
CN202111073775 2021-09-14
CN2021112259286 2021-10-21
CN202111225928 2021-10-21
PCT/CN2022/100016 WO2022268051A1 (zh) 2021-06-21 2022-06-21 稠合四环类化合物、其制备方法及其在医药上的应用

Publications (1)

Publication Number Publication Date
CN117255793A true CN117255793A (zh) 2023-12-19

Family

ID=84544976

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202280030759.7A Pending CN117255793A (zh) 2021-06-21 2022-06-21 稠合四环类化合物、其制备方法及其在医药上的应用

Country Status (11)

Country Link
US (1) US20240327434A1 (https=)
EP (1) EP4361157A4 (https=)
JP (1) JP2024522766A (https=)
KR (1) KR20240024903A (https=)
CN (1) CN117255793A (https=)
AU (1) AU2022297474A1 (https=)
BR (1) BR112023024646A2 (https=)
CA (1) CA3220929A1 (https=)
MX (1) MX2023015533A (https=)
TW (1) TW202317587A (https=)
WO (1) WO2022268051A1 (https=)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116867792A (zh) * 2021-02-09 2023-10-10 基因泰克公司 四环氧氮杂䓬化合物及其用途
WO2024131829A1 (zh) * 2022-12-20 2024-06-27 江苏恒瑞医药股份有限公司 一种kras g12d抑制剂的结晶形式及制备方法
CN119490512A (zh) * 2024-01-26 2025-02-21 苏州盛迪亚生物医药有限公司 一种苯并噻吩取代稠环化合物的可药用盐、其结晶形式及用途
CN119661555A (zh) * 2024-01-26 2025-03-21 苏州盛迪亚生物医药有限公司 一种稠环类化合物的可药用盐、其结晶形式及用途
CN119684315A (zh) * 2024-01-26 2025-03-25 苏州盛迪亚生物医药有限公司 一种苯并噻吩取代稠环化合物的结晶形式及其制备方法
WO2025153038A1 (en) * 2024-01-17 2025-07-24 Suzhou Zanrong Pharma Limited Kras inhibitors and uses thereof

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3211725A1 (en) * 2021-03-17 2022-09-22 Tao Jiang Pyrimidine-fused cyclic compound, preparation method therefor and use thereof
AU2022303440A1 (en) * 2021-07-02 2024-02-22 Shanghai De Novo Pharmatech Co., Ltd. Kras g12d inhibitor and use thereof
WO2023001141A1 (en) * 2021-07-23 2023-01-26 Shanghai Zion Pharma Co. Limited Kras g12d inhibitors and uses thereof
TW202315626A (zh) * 2021-08-31 2023-04-16 大陸商勁方醫藥科技(上海)有限公司 嘧啶并環類化合物及其製法和用途
US20250034166A1 (en) * 2021-09-27 2025-01-30 Jacobio Pharmaceuticals Co., Ltd. Polycyclic fused ring derivatives and use thereof
EP4471037A1 (en) * 2022-01-30 2024-12-04 Shanghai Pharmaceuticals Holding Co., Ltd. Quinoline compound and use thereof
CA3243798A1 (en) 2022-02-09 2023-08-17 Quanta Therapeutics, Inc. Kras Modulators and Their Uses
CR20240508A (es) * 2022-05-19 2024-12-20 Genentech Inc Compuestos aza-tetracíclicos de oxazepina y usos de los mismos
WO2023230190A1 (en) 2022-05-25 2023-11-30 Quanta Therapeutics, Inc. Pyrimidine based modulators and uses thereof
CN119790058A (zh) * 2022-07-09 2025-04-08 荣山医药股份有限公司 用于治疗疾病的稠合环kras抑制剂
WO2024022444A1 (zh) * 2022-07-27 2024-02-01 江苏恒瑞医药股份有限公司 稠环类化合物、其制备方法及其在医药上的应用
AU2023314335A1 (en) * 2022-07-29 2025-02-27 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Pharmaceutical composition comprising kras g12d inhibitor
CN119585278A (zh) * 2022-08-05 2025-03-07 杭州中美华东制药有限公司 具有KRas G12D抑制作用的化合物
IL318647A (en) 2022-08-05 2025-03-01 Kumquat Biosciences Inc Heterocyclic compounds and their uses
WO2024041573A1 (en) * 2022-08-25 2024-02-29 Zai Lab (Shanghai) Co., Ltd. Fused multi-heterocyclic compounds as kras g12d modulators and uses thereof
TW202426459A (zh) * 2022-09-23 2024-07-01 大陸商勁方醫藥科技(上海)有限公司 嘧啶并環類化合物及其製法和用途
AU2023388747A1 (en) * 2022-12-07 2025-07-10 Jacobio Pharmaceuticals Co., Ltd. Fused cyclic compounds and use thereof
WO2024149214A1 (en) * 2023-01-10 2024-07-18 Nikang Therapeutics, Inc. Bifunctional compounds for degrading kras-12d via ubiquitin proteasome pathway
WO2024234360A1 (en) * 2023-05-18 2024-11-21 Nikang Therapeutics , Inc. Tetracyclic derivatives as kras inhibitors
WO2024159471A1 (en) * 2023-02-02 2024-08-08 Nikang Therapeutics , Inc. Tetracyclic derivatives as kras inhibitors
KR20260041941A (ko) 2023-03-15 2026-03-27 콴타 테라퓨틱스, 인크. Kras 조절 인자 및 이의 용도
WO2024208305A1 (zh) * 2023-04-07 2024-10-10 江苏恒瑞医药股份有限公司 稠合四环类化合物、其制备方法及其在医药上的应用
EP4695262A1 (en) * 2023-04-10 2026-02-18 Pfizer Inc. Pyrido[4,3-d]pyrimidine compounds
WO2024218686A1 (en) * 2023-04-20 2024-10-24 Pfizer Inc. Pyrido[4,3-d]pyrimidine compounds
AU2024306338A1 (en) * 2023-06-30 2026-01-08 Gilead Sciences, Inc. Kras modulating compounds
CN121399088A (zh) 2023-07-13 2026-01-23 上海森辉医药有限公司 Kras g12d中间体的制备方法
TW202517649A (zh) * 2023-07-18 2025-05-01 大陸商泰勵生物科技（上海）有限公司 具有抗ｋｒａｓ突變腫瘤活性的化合物
WO2025045141A1 (en) * 2023-08-31 2025-03-06 Suzhou Zanrong Pharma Limited Kras inhibitors and uses thereof
US20250109147A1 (en) 2023-09-08 2025-04-03 Gilead Sciences, Inc. Kras g12d modulating compounds
US20250114346A1 (en) 2023-10-09 2025-04-10 Incyte Corporation Combination therapy using a kras g12d inhibitor and pd-1 inhibitor or pd-l1 inhibitor
US20250114339A1 (en) 2023-10-09 2025-04-10 Incyte Corporation Combination therapy comprising a kras g12d inhibitor and an egfr inhibitor
AU2024374420A1 (en) * 2023-11-02 2026-04-16 Kumquat Biosciences Inc. Degraders and uses thereof
WO2025108443A2 (en) * 2023-11-23 2025-05-30 Beigene Switzerland Gmbh Heterocyclic compounds, compositions thereof, and methods of treatment therewith
WO2025146194A1 (en) * 2024-01-05 2025-07-10 Jacobio Pharmaceuticals Co., Ltd. Fused tetracyclic compounds and use thereof
WO2025157261A1 (zh) * 2024-01-26 2025-07-31 江苏恒瑞医药股份有限公司 G12d抑制剂化合物晶型及其制备方法

Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020146613A1 (en) * 2019-01-10 2020-07-16 Mirati Therapeutics, Inc. Kras g12c inhibitors
WO2021041671A1 (en) * 2019-08-29 2021-03-04 Mirati Therapeutics, Inc. Kras g12d inhibitors
WO2021107160A1 (en) * 2019-11-29 2021-06-03 Taiho Pharmaceutical Co., Ltd. A compound having inhibitory activity against kras g12d mutation
CN115557974A (zh) * 2021-07-02 2023-01-03 上海迪诺医药科技有限公司 Kras g12d抑制剂及其应用
CN116113632A (zh) * 2021-03-30 2023-05-12 浙江海正药业股份有限公司 杂环类衍生物、其制备方法及其医药上的用途
CN117043167A (zh) * 2021-03-17 2023-11-10 劲方医药科技(上海)有限公司 嘧啶并环类化合物及其制法和用途
CN117083281A (zh) * 2021-03-24 2023-11-17 南京明德新药研发有限公司 嘧啶并杂环类化合物及其应用
CN117083280A (zh) * 2021-03-07 2023-11-17 北京加科思新药研发有限公司 Kras g12d抑制剂的稠环衍生物
CN119365467A (zh) * 2022-05-19 2025-01-24 基因泰克公司 氮杂-四环氧氮杂䓬化合物及其用途
CN119487038A (zh) * 2022-04-21 2025-02-18 吉利德科学公司 Kras g12d调节化合物

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017172979A1 (en) 2016-03-30 2017-10-05 Araxes Pharma Llc Substituted quinazoline compounds and methods of use
EP3621968A1 (en) * 2017-05-11 2020-03-18 Astrazeneca AB Heteroaryl compounds that inhibit g12c mutant ras proteins
US10745385B2 (en) * 2017-05-25 2020-08-18 Araxes Pharma Llc Covalent inhibitors of KRAS
TW202012415A (zh) * 2018-05-08 2020-04-01 瑞典商阿斯特捷利康公司 化學化合物
TW202110837A (zh) 2019-05-24 2021-03-16 大陸商江蘇恆瑞醫藥股份有限公司 氫化吡啶并嘧啶類衍生物、其製備方法及其在醫藥上的應用
WO2021000885A1 (zh) * 2019-07-01 2021-01-07 江苏恒瑞医药股份有限公司 喹唑啉酮类衍生物、其制备方法及其在医药上的应用
CA3210167A1 (en) * 2021-02-09 2022-08-18 Genentech, Inc. Tetracyclic oxazepine compounds and uses thereof
WO2023001141A1 (en) * 2021-07-23 2023-01-26 Shanghai Zion Pharma Co. Limited Kras g12d inhibitors and uses thereof
CN116323625A (zh) * 2021-08-25 2023-06-23 浙江海正药业股份有限公司 杂环类衍生物、其制备方法及其医药上的用途
TW202315626A (zh) * 2021-08-31 2023-04-16 大陸商勁方醫藥科技(上海)有限公司 嘧啶并環類化合物及其製法和用途
WO2023103906A1 (zh) * 2021-12-07 2023-06-15 贝达药业股份有限公司 Kras g12d抑制剂及其在医药上的应用
EP4471037A1 (en) * 2022-01-30 2024-12-04 Shanghai Pharmaceuticals Holding Co., Ltd. Quinoline compound and use thereof

Patent Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020146613A1 (en) * 2019-01-10 2020-07-16 Mirati Therapeutics, Inc. Kras g12c inhibitors
WO2021041671A1 (en) * 2019-08-29 2021-03-04 Mirati Therapeutics, Inc. Kras g12d inhibitors
WO2021107160A1 (en) * 2019-11-29 2021-06-03 Taiho Pharmaceutical Co., Ltd. A compound having inhibitory activity against kras g12d mutation
CN117083280A (zh) * 2021-03-07 2023-11-17 北京加科思新药研发有限公司 Kras g12d抑制剂的稠环衍生物
CN117043167A (zh) * 2021-03-17 2023-11-10 劲方医药科技(上海)有限公司 嘧啶并环类化合物及其制法和用途
CN117083281A (zh) * 2021-03-24 2023-11-17 南京明德新药研发有限公司 嘧啶并杂环类化合物及其应用
CN116113632A (zh) * 2021-03-30 2023-05-12 浙江海正药业股份有限公司 杂环类衍生物、其制备方法及其医药上的用途
CN115557974A (zh) * 2021-07-02 2023-01-03 上海迪诺医药科技有限公司 Kras g12d抑制剂及其应用
CN119487038A (zh) * 2022-04-21 2025-02-18 吉利德科学公司 Kras g12d调节化合物
CN119365467A (zh) * 2022-05-19 2025-01-24 基因泰克公司 氮杂-四环氧氮杂䓬化合物及其用途

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116867792A (zh) * 2021-02-09 2023-10-10 基因泰克公司 四环氧氮杂䓬化合物及其用途
WO2024131829A1 (zh) * 2022-12-20 2024-06-27 江苏恒瑞医药股份有限公司 一种kras g12d抑制剂的结晶形式及制备方法
WO2025153038A1 (en) * 2024-01-17 2025-07-24 Suzhou Zanrong Pharma Limited Kras inhibitors and uses thereof
CN119490512A (zh) * 2024-01-26 2025-02-21 苏州盛迪亚生物医药有限公司 一种苯并噻吩取代稠环化合物的可药用盐、其结晶形式及用途
CN119613432A (zh) * 2024-01-26 2025-03-14 苏州盛迪亚生物医药有限公司 一种苯并噻吩取代稠环化合物的可药用盐、其结晶形式及用途
CN119661555A (zh) * 2024-01-26 2025-03-21 苏州盛迪亚生物医药有限公司 一种稠环类化合物的可药用盐、其结晶形式及用途
CN119661556A (zh) * 2024-01-26 2025-03-21 苏州盛迪亚生物医药有限公司 一种稠环类化合物的可药用盐、其结晶形式及用途
CN119684314A (zh) * 2024-01-26 2025-03-25 苏州盛迪亚生物医药有限公司 一种稠环类化合物的可药用盐、其结晶形式及用途
CN119684315A (zh) * 2024-01-26 2025-03-25 苏州盛迪亚生物医药有限公司 一种苯并噻吩取代稠环化合物的结晶形式及其制备方法

Also Published As

Publication number Publication date
EP4361157A4 (en) 2024-10-16
AU2022297474A1 (en) 2024-01-18
BR112023024646A2 (pt) 2024-03-05
KR20240024903A (ko) 2024-02-26
US20240327434A1 (en) 2024-10-03
WO2022268051A1 (zh) 2022-12-29
MX2023015533A (es) 2024-01-23
CA3220929A1 (en) 2022-12-29
TW202317587A (zh) 2023-05-01
JP2024522766A (ja) 2024-06-21
EP4361157A1 (en) 2024-05-01

Similar Documents

Publication Publication Date Title
CN117255793A (zh) 稠合四环类化合物、其制备方法及其在医药上的应用
CN119365465A (zh) 稠环类化合物、其制备方法及其在医药上的应用
EP4592295A1 (en) Pyrimidine-fused ring compound, and preparation method therefor and use thereof
CN113980032B (zh) 稠合四环类衍生物、其制备方法及其在医药上的应用
CN117203207A (zh) 桥环类化合物、其制备方法及其在医药上的应用
CN115385937A (zh) 嘧啶并环烷基类化合物、其制备方法及其在医药上的应用
CN120282969A (zh) 稠合三环类化合物、其制备方法及其在医药上的应用
CN117486901A (zh) 稠合哌啶类化合物、其制备方法及其在医药上的应用
CN115368383A (zh) 稠合含氮杂环类化合物、其制备方法及其在医药上的应用
CN113801114B (zh) 稠合二环杂芳基类衍生物、其制备方法及其在医药上的应用
WO2024002373A1 (zh) 取代嘧啶并环类抑制剂及其制备方法和应用
WO2025092798A1 (zh) 稠合杂芳基类化合物、其制备方法及其在医药上的应用
CN115385938A (zh) 苯并嘧啶类化合物、其制备方法及其在医药上的应用
CN120230123A (zh) 稠环类化合物、其制备方法及其在医药上的应用
CN120365289A (zh) 稠环类化合物、其制备方法及其在医药上的应用
TW202313630A (zh) 含氮雜環類化合物、其製備方法及其在醫藥上的應用
CN116981666B (zh) 稠合四环类化合物、其制备方法及其在医药上的应用
CN114907377A (zh) 稠合四环类化合物、其制备方法及其在医药上的应用
CN120535536A (zh) 稠合杂芳基类化合物、其制备方法及其在医药上的应用
CN114907349A (zh) 稠合的氮杂三环类衍生物、其制备方法及其在医药上的应用
CN114907340A (zh) 稠合的氮杂三环类衍生物、其制备方法及其在医药上的应用
TW202136269A (zh) 稠合二環類衍生物、其製備方法及其在醫藥上的應用
CN113912608B (zh) 嘧啶并嘧啶酮类衍生物、其制备方法及其在医药上的应用
CN114456173B (zh) 稠环基取代的环己二酰亚胺类衍生物、其制备方法及其在医药上的应用
CN120829440A (zh) 多环类化合物、其制备方法及其在医药上的应用

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40105524

Country of ref document: HK